Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, April 2005, p. 1509-1520, Vol. 49, No. 4
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.4.1509-1520.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Tina M. Kish-Catalone,1,
Elizabeth B. Neely,1
Lynn R. Budgeon,2
Mary L. Ferguson,1
Catherine Stiller,1
Shendra R. Miller,1
Daniel Malamud,3
Fred C. Krebs,4
Mary K. Howett,5 and
Brian Wigdahl4*
Departments of Microbiology and Immunology,1 Pathology, The Pennsylvania State University College of Medicine, Hershey,2 Department of Biochemistry, University of Pennsylvania School of Dental Medicine,3 Department of Microbiology and Immunology and Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine,4 Department of Bioscience and Biotechnology, Drexel University, Philadelphia, Pennsylvania5
Received 16 April 2004/ Returned for modification 28 May 2004/ Accepted 1 December 2004
C31G is currently the focus of clinical trials designed to evaluate this agent as a microbicidal and spermicidal agent. In the following studies, the in vivo safety of C31G was assessed with a Swiss Webster mouse model of cervicovaginal toxicity and correlated with results from in vitro cytotoxicity experiments and published clinical observations. A single exposure of unformulated 1% C31G resulted in mild-to-moderate epithelial disruption and inflammation at 2 and 4 h postapplication. The columnar epithelium of the cervix was the primary site of damage, while no perturbation of the vaginal mucosa was observed. In contrast, application of unformulated 1.7% C31G resulted in greater levels of inflammation in the cervical epithelium at 2 h postapplication and severe epithelial disruption that persisted to 8 h postapplication. Application of a nonionic aqueous gel formulation containing 1% C31G resulted in no apparent cervicovaginal toxicity at any time point evaluated. However, formulation of 1.7% C31G did not substantially reduce the toxicity associated with unformulated C31G at that concentration. These observations correlate with findings gathered during a recent clinical trial, in which once-daily applications resulted in no adverse events in women receiving the formulation containing 1% C31G, compared to moderate-to-severe adverse events in 30% of women receiving the 1.7% C31G formulation. The Swiss Webster mouse model was able to effectively discriminate between concentrations and formulations of C31G that produced distinct clinical effects in human trials. The Swiss Webster animal model may be a highly valuable tool for preclinical evaluation of candidate vaginal microbicides.
Present address: Chesapeake Biological Laboratories, Inc., Baltimore, MD 21230.
Present address: Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD 21201.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»